Beijing Kere Biotechnology

Beijing Kere Biotechnology is a clinical-stage Chinese biotechnology company specializing in the development of innovative immunotherapies based on heat shock protein (HSP) technology. The company's core focus is the development of autologous and recombinant HSP70-based vaccines and therapeutics designed to stimulate the immune system against various solid tumors. Its lead candidate, a recombinant human heat shock protein 70 (rhHSP70), has been investigated in clinical trials for indications including liver and pancreatic cancers. By leveraging the chaperone properties of HSPs to enhance antigen presentation, Beijing Kere aims to provide effective treatment options for patients with refractory malignancies.